Dr. Gaynor serves as President, Chief of Research and Development at BioNTech US (previously Neon Therapeutics, Inc.), a leading company in the field of neoantigen-targeted cancer therapies. From November 2016 until May 2020, he was President of Research and Development at Neon Therapeutics. Prior to joining Neon, Dr. Gaynor held clinical development and medical affairs roles at Eli Lilly and Company from August 2002 to October 2016, including serving as Senior Vice President, Clinical Development and Medical Affairs of Lilly Oncology. Dr. Gaynor, a licensed physician with board certifications in oncology and hematology, started his career in academia, initially serving on the faculty at UCLA School of Medicine for nine years, followed by eleven years at the University of Texas Southwestern Medical School, during which he spent time as the Chief of Hematology-Oncology and Director of the Simmons Cancer Center. Dr. Gaynor is on the editorial boards of several scientific journals and has published extensively, including more than 140 scientific articles. He also serves on the Boards of Directors of Infinity Pharmaceuticals, Inc., Zai Lab Limited and the Damon Runyon Cancer Research Foundation, while also sitting on several committees for the American Association of Cancer Research and other leading cancer organizations.